Opko Health Inc (OPK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Opko Health Inc (OPK) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.31 Million) by net assets ($1.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Opko Health Inc fund operations to measure how many days the company can operate on defensive assets alone.
Opko Health Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Opko Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Opko Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opko Health Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hefei Kewell Power System Co Ltd
SHG:688551
|
0.001x |
|
Global Mixed-Mode Technology Inc
TW:8081
|
0.069x |
|
Yunding Technology Co Ltd
SHE:000409
|
-0.041x |
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
0.414x |
|
Nhn Entertain
KO:181710
|
-0.093x |
|
Gryphon Capital Income Trust
AU:GCI
|
-0.161x |
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
0.216x |
|
GL Events SA
PA:GLO
|
0.162x |
Annual Cash Flow Conversion Efficiency for Opko Health Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Opko Health Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Opko Health Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.27 Billion | $-178.54 Million | -0.141x | -4.79% |
| 2024-12-31 | $1.37 Billion | $-183.49 Million | -0.134x | -562.07% |
| 2023-12-31 | $1.39 Billion | $-28.20 Million | -0.020x | +66.70% |
| 2022-12-31 | $1.56 Billion | $-95.19 Million | -0.061x | -367.93% |
| 2021-12-31 | $1.69 Billion | $38.34 Million | 0.023x | -3.67% |
| 2020-12-31 | $1.67 Billion | $39.48 Million | 0.024x | +122.10% |
| 2019-12-31 | $1.61 Billion | $-172.52 Million | -0.107x | -75.35% |
| 2018-12-31 | $1.79 Billion | $-109.14 Million | -0.061x | -21.99% |
| 2017-12-31 | $1.84 Billion | $-92.08 Million | -0.050x | -426.02% |
| 2016-12-31 | $2.09 Billion | $32.05 Million | 0.015x | -81.51% |
| 2015-12-31 | $1.98 Billion | $164.02 Million | 0.083x | +176.62% |
| 2014-12-31 | $835.80 Million | $-90.38 Million | -0.108x | -62.22% |
| 2013-12-31 | $872.98 Million | $-58.19 Million | -0.067x | +46.68% |
| 2012-12-31 | $203.28 Million | $-25.41 Million | -0.125x | -8.73% |
| 2011-12-31 | $160.88 Million | $-18.50 Million | -0.115x | +86.12% |
| 2010-12-31 | $23.05 Million | $-19.09 Million | -0.828x | -104.90% |
| 2009-12-31 | $57.73 Million | $-23.34 Million | -0.404x | +99.50% |
| 2008-12-31 | $359.00K | $-29.29 Million | -81.599x | -7980.45% |
| 2007-12-31 | $16.78 Million | $-16.95 Million | -1.010x | -2574.56% |
| 2006-12-31 | $8.08 Million | $-305.00K | -0.038x | +63.28% |
| 2005-12-31 | $8.72 Million | $-897.00K | -0.103x | +36.41% |
| 2004-12-31 | $9.83 Million | $-1.59 Million | -0.162x | +71.45% |
| 2003-12-31 | $10.30 Million | $-5.84 Million | -0.566x | -3.00% |
| 2002-12-31 | $16.07 Million | $-8.84 Million | -0.550x | -79.44% |
| 2001-12-31 | $26.12 Million | $-8.01 Million | -0.306x | -119.84% |
| 2000-12-31 | $35.77 Million | $-4.99 Million | -0.139x | +88.80% |
| 1999-12-31 | $2.59 Million | $-3.23 Million | -1.245x | -216.43% |
| 1998-12-31 | $6.10 Million | $-2.40 Million | -0.393x | +85.08% |
| 1997-12-31 | $1.10 Million | $-2.90 Million | -2.636x | -142.55% |
| 1996-12-31 | $2.30 Million | $-2.50 Million | -1.087x | -171.74% |
| 1995-12-31 | $5.00 Million | $-2.00 Million | -0.400x | -- |
About Opko Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigen… Read more